-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Oxycodone MR + Promethazine IR) in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Oxycodone MR + Promethazine IR) in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Oxycodone MR + Promethazine IR) in Pain Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Orenipro IR in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orenipro IR in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orenipro IR in Pulmonary Arterial Hypertension Drug Details: Orenipro (oral...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalfampridine IR in Spinocerebellar Ataxia (SCA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalfampridine IR in Spinocerebellar Ataxia (SCA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dalfampridine IR in Spinocerebellar Ataxia (SCA) Drug Details: Dalfampridine is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pramipexol Dihydrochloride IR in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pramipexol Dihydrochloride IR in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pramipexol Dihydrochloride IR in Major Depressive Disorder Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Capsulin IR in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Capsulin IR in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Capsulin IR in Type 1 Diabetes (Juvenile Diabetes)...
-
Product Insights
Ir. H. Djuanda
Ir. H. Djuanda is a Hydro project located in West Java, Indonesia. The project came online in 1967. Empower your strategies with our Ir. H. Djuanda report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons...
-
Analyst Opinions
NewNew Prescription – Generative AI Meets Healthcare (Vol. 2)
GlobalData's latest Innovation Radar report "New Prescription: Generative AI Meets Healthcare (Vol. 2)," expands upon its predecessor and digs further into the transformative capabilities of generative AI within the pharmaceutical and healthcare sectors. This volume dives into recent real-world applications where generative AI is advancing across drug discovery, diagnostics, clinical documentation, and patient support. From harnessing vast datasets to expediting R&D breakthroughs and refining patient care through lifelike speech synthesis, this report unveils the ongoing evolution of generative AI in...
-
Product Insights
NewNet Present Value Model: Xenon Pharmaceuticals Inc’s Ezogabine IR
Empower your strategies with our Net Present Value Model: Xenon Pharmaceuticals Inc's Ezogabine IR report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Analyst Opinions
NewAI Compute – How Chips Drive Next Industrial Leap
AI Chips Trend Analysis Report Overview GlobalData's "AI Compute: How Chips Drive Next Industrial Leap," innovation radar report explores the transformative impact of semiconductor chip innovations, particularly AI chips, across various industries such as healthcare, telecom, and energy & utilities. The report illuminates how advanced chips are enhancing computational power, enabling improved analytics, and driving automation. By reshaping industrial processes, these technologies are boosting efficiency and fostering innovation. The “AI Compute” report provides strategic insights to help businesses capitalize on...
-
Sector Analysis
NewOman Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Oman Defense Market Report Overview The Oman defense budget is $8 billion in 2024. The country’s defense budget will grow at a CAGR of more than 2% during 2025-2029. This can be attributed to the rising arms race in the region to intercept the growing turbulence in neighboring countries such as Syria and Yemen. In addition, the increase in oil prices will facilitate increases in Oman's defense budget. Oman Defense Market Outlook, 2024-2029 ($ Billion) Buy the Full Report for...